filecrux
Oct 28, 9:18 PM
$NEO Does NeoGenomics' unflagged raise to about
$60M in adjusted EBITDA guidance mark a real turn in profit?
🚀 NeoGenomics, a Florida cancer-testing lab worth about
$2.31B at
$18 a share at 16:19 ET on October 28, 2026, raised its full-year 2026 adjusted EBITDA guidance to about
$60M from
$56M–
$58M
🚀 The new figure is about 5% above the old midpoint, while the company's October 5, 2026 8-K release had said it was reiterating that EBITDA guidance and flagged an increase only for revenue
⚠️ The
$60M full-year guide implies about
$17.9M of fourth-quarter adjusted EBITDA after
$42.1M in the first nine months, below the third quarter's
$18.7M but up from about
$13.0M in the fourth quarter of 2025
📅 Next: Warren Stone, now President and COO, becomes CEO effective January 4, 2027, when Tony Zook moves to Executive Chairman
Source: SEC 8-K, Oct 28 + SEC 8-K, Oct 5
0 replies